Verily and Samsung announced a partnership to integrate Galaxy smartwatch data into Verily’s Pre platform, creating an end‑to‑end system for deploying wearables in clinical studies and analyzing continuous patient data remotely. The collaboration targets pharmaceutical researchers seeking scalable, validated digital endpoints and remote monitoring capabilities for trials. Verily framed the integration as streamlining device deployment, data ingestion and analysis for sponsors. The deal signals growing industry acceptance of consumer wearables as clinical tools and underscores the need for validated, regulatory‑grade pipelines for digital biomarker use. Sponsors and CROs will monitor how Verily standardizes data quality, device calibration, and privacy controls across large trial populations.